Choosing first-line Hodgkin lymphoma treatment: a practical decision guide

First-line treatment is the initial complete treatment pathway for the current Hodgkin lymphoma diagnosis. It is not a ranking that places one medicine above every other medicine. For newly diagnosed classical Hodgkin lymphoma, the team usually aims for durable disease control with a program that can be completed while limiting short-term and later harm. The first choice also determines which tests and response-based decisions will follow.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Early favorable, early unfavorable, and advanced classical disease have different evidence bases. Baseline PET, mass measurements, involved regions, extranodal findings, symptoms, and relevant laboratory results help establish the group. Ask which classification system is being used, especially for stage II disease with a large mediastinal mass or other unfavorable feature. The shortest regimen is not selected from the stage numeral alone. [S23]
The calendar should show infusions, blood tests, reviews, and the intended PET window while allowing medically necessary changes. A cycle may contain more than one treatment visit; its length and total number depend on the regimen. Know which appointment corresponds to the cycle and day written in the prescription. Counting hospital admissions alone can misrepresent how much therapy has actually been delivered. [S20]
Ask the receiving team to review available records, confirm the likely pathway, and state when pathology review and treatment initiation can occur. Travel plans must account for repeated infusions, urgent care, and PET assessment, plus responsibility if part of the course continues at home. A rapidly deteriorating patient needs local treatment and stabilization assessment; a journey should not become the prerequisite for essential care. [S22]

Quick answer

Full guide

Before signing consent, know the pathological category, stage and clinical risk group, full proposed regimen, and first assessment that could change it. If the diagnosis is nodular lymphocyte-predominant disease or another lymphoma remains in the differential, a standard classical Hodgkin pathway cannot simply be assumed. Resolving that distinction can be more important than choosing between two familiar drug abbreviations. [S2]

Decide which treatment pathway applies

Early favorable, early unfavorable, and advanced classical disease have different evidence bases. Baseline PET, mass measurements, involved regions, extranodal findings, symptoms, and relevant laboratory results help establish the group. Ask which classification system is being used, especially for stage II disease with a large mediastinal mass or other unfavorable feature. The shortest regimen is not selected from the stage numeral alone. [S23]

If one uncertain finding could change the entire pathway, discuss whether additional confirmation is worthwhile. Other uncertainties may not alter the proposed systemic treatment, in which case the clinician can explain why an invasive investigation is unnecessary. Testing should be connected to a decision rather than delaying treatment for an answer that has no practical effect.

For early disease, settle how radiation fits

Suitable patients may receive shorter chemotherapy combined with local radiotherapy, while selected patients follow chemotherapy pathways without radiation. Radiation helps control disease in the original area, but the plan must consider normal-organ exposure and later health. Discuss the actual field and nearby organs, rather than treating all radiation courses as equivalent. [S16][S17]

If radiation is part of the initial plan, involving the radiation oncologist before chemotherapy ends preserves the baseline information and allows early technical planning. If omission will depend on PET, specify the complete chemotherapy program and scoring threshold supporting that strategy. HD17 and early favorable trials did not use interchangeable approaches; a radiation-omission rule from one should not be copied into another treatment program. [S24][S25]

For advanced disease, compare whole regimens

ABVD contains doxorubicin, bleomycin, vinblastine, and dacarbazine. Other discussions include nivolumab-AVD, brentuximab vedotin-AVD, and PET-guided BrECADD for appropriate patients. Their components, evidence, monitoring, support needs, cost, and toxicity differ. Comparing the first infusion price or an advertised response percentage cannot establish the better complete treatment. [S1][S6]

Nivolumab is a PD-1 inhibitor, whereas brentuximab vedotin is an antibody-drug conjugate. S1826 directly compared their respective AVD combinations in untreated advanced classical Hodgkin lymphoma. That provides strong evidence for the comparison studied; it was not a direct comparison of nivolumab-AVD against every other possible regimen. Claims that it must outperform all alternatives for every patient go beyond that study. [S4]

The US FDA approved nivolumab-AVD in March 2026 for previously untreated stage III or IV classical disease in adults and children aged 12 years and older. Treatment in China requires a separate check of current local product information and prescribing arrangements. China's official 2025 guidance places several PD-1 medicines in defined relapsed or refractory settings, while some foreign first-line brentuximab indications appear under separately marked additional indications. Those entries should not all be represented as Chinese first-line approvals. [S3][S7]

Identify health factors that affect the choice

A proposed bleomycin-containing program calls for attention to lung disease and respiratory symptoms. Doxorubicin raises cardiac considerations. Existing numbness, balance problems, or difficulty with fine hand movements should be described before medicines that can worsen neuropathy are selected. Toxicity planning belongs before the first dose, not only after complications appear.

Before checkpoint therapy, disclose autoimmune disease, organ or stem cell transplantation, and ongoing steroid or other immunosuppressive treatment. These situations need individual specialist assessment rather than a patient deciding that immunotherapy is either certainly prohibited or entirely safe. The team should explain how immune adverse effects will be assessed outside routine infusion appointments. [S7]

For an older, frail, or medically complex patient, clarify the treatment goal and tolerable intensity. A modification can help make the whole course feasible, but it should identify the changed drugs, rationale, and response plan. A referral that says only “elderly regimen” does not provide enough detail for another hospital or an emergency department.

Address fertility before treatment starts

Fertility can be overlooked when everyone is focused on starting chemotherapy promptly. People who want to preserve future options should ask immediately about sperm, egg, or embryo preservation and other relevant services. The discussion is appropriate even without a current partner or immediate parenting plans, particularly when the proposed regimen carries substantial gonadal risk. [S10][S11]

The available time depends on disease urgency and the preservation method. Hematology and reproductive specialists should coordinate so that the patient understands what can be offered without an inappropriate delay. If preservation is declined or impossible, document the discussion, reasons, and future assessment route. Patients should not first learn about reproductive consequences after completing treatment.

Turn the prescription into a usable calendar

The calendar should show infusions, blood tests, reviews, and the intended PET window while allowing medically necessary changes. A cycle may contain more than one treatment visit; its length and total number depend on the regimen. Know which appointment corresponds to the cycle and day written in the prescription. Counting hospital admissions alone can misrepresent how much therapy has actually been delivered. [S20]

Confirm whether central venous access is needed, which medicines prevent nausea or infection, how home medicines are taken, and whom to contact after a missed dose. Have the oncology pharmacist or doctor review the cancer prescription alongside chronic-disease medicines. A family member can help organize this information, but the patient should also have an accessible list and contact numbers.

Planning transport and support is part of preparation. Ask whether an accompanying person is needed for the first visit or after particular medicines, how unexpected admissions are handled, and whether local blood testing is acceptable between visits. These details make the chosen regimen practicable rather than merely theoretically suitable.

Use the first cycle to describe tolerance accurately

Report fever, marked weakness, persistent vomiting, inadequate fluid intake, or breathing problems according to the team's instructions. Infection during chemotherapy can deteriorate rapidly. Contact the team before masking fever with repeated antipyretics, and use urgent care for concerning symptoms rather than waiting for the next infusion. The clinic should provide a clear temperature threshold and an out-of-hours route. [S9]

Record when symptoms started after treatment, how long they lasted, and whether they affected eating, walking, sleep, or self-care. This helps the clinician improve supportive care or alter a drug when necessary. Patients do not need to assign a technical adverse-event grade themselves. Few side effects do not mean treatment is ineffective, and severe side effects do not demonstrate stronger anticancer activity.

Treat interim PET as a planned decision point

Within an appropriate advanced-disease ABVD pathway, early PET response can guide whether bleomycin is omitted later. RATHL supports that conditional adjustment to reduce pulmonary toxicity. Ask whether your scan timing and result satisfy the corresponding criteria. Any negative scan at any time is not automatically permission to stop a component. [S5]

Other regimens use PET differently. An adaptation may depend on a particular risk group, specialist reading standard, and prescribed subsequent treatment. An abnormal scan also does not mean that the patient should independently conclude relapse or failure. The team considers timing, baseline images, infection, and other explanations, sometimes obtaining review or further tissue before changing to salvage therapy. [S2]

When treatment changes, retain the reason in writing. A second center needs to know whether a drug was removed because the protocol allowed it, because of toxicity, or for another clinical reason. Without that explanation, a transferred prescription can inadvertently restore a drug that should remain stopped.

Plan the end-of-treatment assessment

The last chemotherapy infusion is not necessarily the day on which final response can be determined. End-of-treatment PET and other assessments need suitable timing, and planned radiation changes the treatment-completion point. Before discharge, identify the clinician responsible for the final integrated response assessment and the action associated with any unresolved finding.

After remission, do not add medicines independently as extra “insurance” or import a maintenance strategy from another cancer. Further treatment should follow evidence for this disease and the actual pathway. The follow-up record should include cumulative drug exposure, radiation information, major adverse events, and future screening needs. That record becomes important long after the initial course is over. [S13]

Starting first-line care in China

Ask the receiving team to review available records, confirm the likely pathway, and state when pathology review and treatment initiation can occur. Travel plans must account for repeated infusions, urgent care, and PET assessment, plus responsibility if part of the course continues at home. A rapidly deteriorating patient needs local treatment and stabilization assessment; a journey should not become the prerequisite for essential care. [S22]

Discuss costs as separate categories: pathology and staging, medicines and administration, supportive care, response testing, radiation when indicated, and living expenses. Each entry should state renminbi currency, whether it is quoted or unconfirmed, and the assumed cycles or admission days. Medical adjustments need to remain possible. A web package price should never be the reason to omit necessary tests or interrupt treatment without clinical advice. [S12]

When comparing two first-line recommendations, ask both teams to address the same questions: which evidence supports the program, why it fits your risk group, what toxicities matter most, which assessment can change it, and what support is needed to finish. You do not have to prescribe your own treatment, but you should understand the reason for the pathway and how the team will respond when new information arrives.